



TAM DUC CARDIOLOGY HOSPITAL
JOINT STOCK COMPANY

No.: 01.2026/NQ-HĐQT

Ho Chi Minh City, April 24, 2026

DRAFT

RESOLUTION

2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020;
- Pursuant to the Charter of Tam Duc Cardiology Hospital Joint Stock Company approved by the General Meeting of Shareholders on April 28, 2022;
- Pursuant to Resolution No. VII.11/NQ-HĐQT dated March 2, 2026, and Notice No. 08-26/CV-TĐ issued by the Chairman of the Board of Directors on March 3, 2026, and based on the list of shareholders entitled to attend and vote at the 2026 Annual General Meeting of Shareholders as of the record date of March 24, 2026, as provided by the Vietnam Securities Depository and Clearing Corporation;

On April 24, 2026, at 08:... a.m., at Tam Duc Cardiology Hospital, No. 4 Nguyen Luong Bang Street, Tan My Ward, Ho Chi Minh City, the 2026 Annual General Meeting of Shareholders was convened with ... shareholders attending, representing ... shares, equivalent to ...% of the Company's total outstanding shares (...../15,552,000 shares).

- Pursuant to the Vote Counting Record of the Vote Counting Committee of the 2026 General Meeting of Shareholders dated April 24, 2026;
- Pursuant to the Meeting Minutes of the 2026 Annual General Meeting of Shareholders of Tam Duc Cardiology Hospital Joint Stock Company dated April 24, 2026.

The meeting discussed and unanimously approved the Resolution with the following contents:

Article 1. APPROVAL OF THE 2025 PERFORMANCE REPORT AND 2025 AUDITED FINANCIAL STATEMENTS

Regarding professional activities: In 2025, medical examination activities *were equivalent to* 2024 (81,083/ 81,428). Inpatient treatment *increased by 5%* compared to 2024 (4,565/ 4,344). A total of 270 *surgical cases* were performed, *a decrease of 24% compared to 2024* (270/355). Interventional cardiology *increased by 4%* compared to 2024 (1,755/1,689). Cardiac electrophysiology activities in 2025 *increased by 10%* compared to 2024 (507/461). Paraclinical services in 2025 *increased by 3%* compared to 2024 (1,014,560/ 984,869).

Regarding financial performance:

	<i>2025 Plan</i>	<i>2025 Actual</i>
Total revenue:	VND 750 billion	VND 846.1 billion
Profit before tax:	VND 92 billion	VND 108.2 billion
Profit after tax:	VND 84 billion	VND 95.7 billion

The financial results for 2025 exceeded the plan, with revenue increasing by 12.8%.

Profit before tax reached VND 108.2 billion, an increase of 17.7% compared to the 2025 plan.

The pre-tax profit/total revenue ratio for 2025 is 12.79% (compared to 12.1% in 2024).

Voting:

Article 2. APPROVAL OF THE SUPERVISORY BOARD'S REPORT FOR 2025

Voting:

Article 3. APPROVAL OF THE PROFIT DISTRIBUTION PLAN FOR 2025. THE DIVIDEND RATE FOR 2025 IS 33% AS APPROVED BY THE 2025 GENERAL MEETING OF SHAREHOLDERS ON APRIL 25, 2025

Criteria	Amount (VND)
1. Profit After Tax for 2025	95,735,394,301
2. Allocation to Funds (Resolution 01.2025/NQ-ĐHCD dated April 25, 2025)	6,946,474,195
2.1. Board of Directors' Operating Fund (3.6% of PAT)	3,446,474,195
2.2. Reward and Welfare Fund	3,500,000,000
3. Remaining Profit for Dividend Distribution (3=1-2)	88,788,920,106
4. Dividend Distribution - Projected 33% of par value	54,022,736,000
4.1. First interim dividend, August 2025: 10%	16,370,526,000
4.2. Second interim dividend, February 2026: 10%	16,370,526,000
4.3. Third dividend payment (after approval by the General Meeting): 13%	21,281,684,000
5. Remaining Profit for 2025 (5=3-4)	34,766,184,106

Voting:

Article 4. APPROVAL OF THE PROPOSAL TO AUTHORIZE THE BOARD OF DIRECTORS TO SELECT AN AUDIT FIRM FOR THE 2026 FINANCIAL STATEMENTS

The General Meeting of Shareholders authorizes the Board of Directors to decide on the selection of an audit firm for the 2026 financial statements.

Voting:

Article 5. APPROVAL OF THE 2026 BUSINESS PERFORMANCE PLAN

Regarding personnel: *After 20 years of stable operation and development, the leadership and professional team of Tam Duc have matured. However, it is necessary to continue recruiting and providing advanced training in key technical positions such as emergency resuscitation, anesthesia and resuscitation, surgery, interventional cardiology, and cardiac electrophysiology, while focusing on nurturing key staff and future leadership to ensure sustainable development in the next phase.*

Regarding expertise: *In 2026, medical examination, emergency care, and inpatient treatment are expected to increase by 5% compared to 2025. The company will continue to develop specialized techniques and maintain stable professional quality, with targets including 300 cardiac surgeries, 1,500 interventional cardiac catheterizations, and 500 cardiac electrophysiology cases.*

Regarding finance:

<i>Total revenue:</i>	<i>VND 780 billion</i>
<i>Profit before tax:</i>	<i>VND 95 billion</i>
<i>Profit after tax:</i>	<i>VND 86 billion</i>
<i>Dividends:</i>	<i>20% of par value</i>

Voting:

Article 6. APPROVAL OF THE 2026 FUND ALLOCATION PLAN

Board of Directors' Operating Fund: 3.6% of profit after tax

Reward and Welfare Fund: VND 3.5 billion

Voting:

Article 7. APPROVAL OF THE 2026 DIVIDEND PAYMENT PLAN

First interim dividend for 2026 at a rate of 5% of par value: September 2026

Second interim dividend for 2026 at a rate of 5% of par value: January 2027

Third interim dividend for 2026 at a rate of 10% of par value: After the 2027 General Meeting of Shareholders

Voting:

Article 8. APPROVAL OF THE PLAN FOR ISSUANCE OF SHARES TO INCREASE CHARTER CAPITAL FOR 2026 AS ATTACHED TO THE PROPOSAL NO. 02/TTtr-HĐQT DATED MARCH 30, 2026 OF THE BOARD OF DIRECTORS

Voting:



Article 9. APPROVAL OF EMPLOYEE REWARDS ON THE OCCASION OF THE 20TH ANNIVERSARY OF TAM DUC CARDIOLOGY HOSPITAL (MARCH 8, 2006 – MARCH 8, 2026) AS ATTACHED TO PROPOSAL NO. 01-2026/TTr-HĐQT DATED MARCH 30, 2026 OF THE BOARD OF DIRECTORS

Voting:

This Resolution was presented at the General Meeting and unanimously approved by the General Meeting of Shareholders at a.m. on April 24, 2026.

CHAIRMAN OF THE BOARD OF DIRECTORS

DR. NGUYEN NGOC CHIEU